GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Operating Income

BeiGene (HKSE:06160) Operating Income : HK$-8,587 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Operating Income?

BeiGene's Operating Income for the three months ended in Mar. 2024 was HK$-2,045 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-8,587 Mil.

Warning Sign:

BeiGene Ltd has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. BeiGene's Operating Income for the three months ended in Mar. 2024 was HK$-2,045 Mil. BeiGene's Revenue for the three months ended in Mar. 2024 was HK$5,880 Mil. Therefore, BeiGene's Operating Margin % for the quarter that ended in Mar. 2024 was -34.77%.

Good Sign:

BeiGene Ltd operating margin is expanding. Margin expansion is usually a good sign.

BeiGene's 5-Year average Growth Rate for Operating Margin % was 31.20% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BeiGene's annualized ROC % for the quarter that ended in Mar. 2024 was -39.97%. BeiGene's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -70.06%.


BeiGene Operating Income Historical Data

The historical data trend for BeiGene's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Operating Income Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,491.47 -12,850.19 -11,220.69 -13,933.26 -9,432.18

BeiGene Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,913.89 -2,496.50 -1,048.77 -2,997.36 -2,044.53

BeiGene Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-8,587 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeiGene  (HKSE:06160) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BeiGene's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-8178.1 * ( 1 - -3.17% )/( (20289.736 + 21927.399)/ 2 )
=-8437.34577/21108.5675
=-39.97 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=45338.037 - 6357.099 - ( 24791.429 - max(0, 14136.621 - 32827.823+24791.429))
=20289.736

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=44338.268 - 6560.994 - ( 21852.534 - max(0, 14720.453 - 30570.328+21852.534))
=21927.399

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

BeiGene's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8178.1/( ( (10854.919 + max(-848.472, 0)) + (12122.654 + max(369.55, 0)) )/ 2 )
=-8178.1/( ( 10854.919 + 12492.204 )/ 2 )
=-8178.1/11673.5615
=-70.06 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2796.119 + 3249.83 + 1694.774) - (6357.099 + 0 + 2232.096)
=-848.472

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3405.305 + 3499.58 + 1563.997) - (6560.994 + 0 + 1538.338)
=369.55

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

BeiGene's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-2044.525/5880.174
=-34.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


BeiGene Operating Income Related Terms

Thank you for viewing the detailed overview of BeiGene's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (HKSE:06160) Business Description

Traded in Other Exchanges
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Oyler John Victor 2101 Beneficial owner
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene (HKSE:06160) Headlines

No Headlines